期刊文献+

洛铂联合紫杉醇同步放化疗对中晚期食管癌的近期疗效 被引量:7

Recent results of concurrent chemoradiotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma
原文传递
导出
摘要 目的观察洛铂联合紫杉醇同步放化疗对中晚期食管癌的近期疗效及患者不良反应。方法回顾性分析2010年4月至2011年5月收治的首程行同步放化疗的中晚期食管鳞状细胞癌患者26例,化疗方案:紫杉醇135mg/m2,第1天;洛铂35mg/m2,第2天,3周重复;放疗于第1周期化疗结束后第2天进行,中位总剂量60Gy,30次,共6周。结果全组共化疗52个周期,平均每例2个周期。近期疗效:完全缓解(CR)7例(26.9%),部分缓解(PR)17例(65.4%),疾病稳定(SD)2例(7.7%),总有效(CR+PR)率为92.3%。患者不良反应:骨髓抑制方而,白细胞下降Ⅰ~Ⅱ度46.1%(12例),Ⅲ~Ⅳ度46.1%(12例),血小板下降Ⅰ~Ⅱ度30.8%(8例),Ⅲ~Ⅳ度7.7%(2例),血红蛋白下降Ⅰ~Ⅱ度42.3%(11例),Ⅲ度15.4%(4例);脱发84.6%(22例);肌肉或关节痛69.2%(18例);胃肠道反应Ⅰ~Ⅱ度11.5%(3例);放射性食管炎88.5%(23例);放射性气管炎19.2%(5例)。结论洛铂联合紫杉醇同步放化疗对中晚期食管癌的近期疗效妤,患者不良反应能够耐受,值得临床进一步研究。 Objective To investigate recent treatment result and the toxic responses of chemoradiotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma. Methods From April 2010 to May 2011, 26 initial treatment patients with advanced esophageal carcinoma were enrolled. The chemotherapy consisted of paclitaxel (135 mg/m2) on day I and lobaplatin (35 mg/m2) on day 2, and one cycle continued 21 days. Radiotherapy started on the second day after the fist cycle of chemotherapy. The median total dose was 60 Gy (2 Gy/Fraction, 30 fractions, completed in 6 weeks). Results There were 52 cycles in all and mean 2 cycles per patient. CR occurred in 7 patients (26.9 %), PR in 17 patients (65.4 %) and SD in 2 patients (7.7 %). The total effective rate was 92.3 % (CR+PR). The toxic responses mainly represented as following, myelotoxicity principally showed leucopenia at grade Ⅰ~Ⅱ occurred 46.1% (12/26) and at grade Ⅲ~Ⅳ 46.1% (12/26), thrombopenia at grade Ⅰ~Ⅱ occurred 30.8 % (8/26) and at grade Ⅲ~Ⅳ 7.7 % (2/26), hypohemoglobinemia at grade Ⅰ~Ⅱ occurred 42.3 % (11/26) and at grade Ⅲ 15.4 % (4/26). Baldness occurred 84.6 % (22/26). Pain of muscles or arthralgia occurred 69.2 % (18/26). Responses of gastrointestinal tract at grade Ⅰ~Ⅱ occurred 11.5 % (3/26). Radiation induced esophagitis occurred 88.5 % (23/26) and traeheitis 19.2 % (5/26). Conclusion The toxic responses of concurrent chemoradiaotherapy with lobaplatin and paclitaxel in advanced esophageal carcinoma are tolerant, and the recent treatment result is good. Further study is needed.
出处 《肿瘤研究与临床》 CAS 2012年第2期105-107,共3页 Cancer Research and Clinic
关键词 食管肿瘤 放射疗法 药物疗法 近期疗效 Esophageal neoplasms Radiotherapy Drug therapy Recent result
  • 相关文献

参考文献9

  • 1Urba SG, Orringer MB, Ianettonni M, et al.Coneurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer, 2003, 98: 2177-2183.
  • 2Polee MB, Tilanus HW, Eskens FA. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol, 2003, 14: 1253-1257.
  • 3Zhao KL, Shi XH, Jiang GL, et al. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squaraous cell carcinoma of the esophagus: a phase III randomized study. Int J Radiat Oncol Biol Phys, 2005, 62: 1014-1020.
  • 4American Joint Committee on Cancer. AJCC cancer staging handbook. 6th ed. Philadelphia: Lippincott-Raven, 2002: 8-10.
  • 5Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria:version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 2000, 47: 13- 47.
  • 6Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys, 1995, 31: 1341-1346.
  • 7McKeage MJ. Lobaplatin: a new antitumour platinum drug. Expert Opin Investig Drugs, 2001, 10: 119,128.
  • 8Schmoll HJ, Kohne CH, Papageorion E, et al. Single agent lobaplatin is active in patients with esophageal squamous cell carcinoma:a phase II evaluation. Proe ASCO, 1995, 14: 483.
  • 9李醒亚,周芳,任中海,赵永福,路平,王俊生,郑安平,库建伟.洛铂联合5-氟尿嘧啶与亚叶酸钙治疗晚期食管癌的Ⅱ期临床研究[J].中华肿瘤防治杂志,2007,14(1):64-66. 被引量:18

二级参考文献4

  • 1孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:97
  • 2McKeage M J.Lobaplatin..a new antitumour platinum drug[J].Expert Opin Investig Drugs,2001,10(1):119-128.
  • 3Therasse P,Arbuek S G,Eisenhauer E A,et al.New guidelines to evaluate the response to treatment in solid tumors[J].Journal of the National Cancer Institute,2000,92 (3):205 -216.
  • 4Mauer M A,Kraut E H,Krauss S A,et al.Phase Ⅱ trial of oxaliplatin,leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus[J].Annals of Oncology,2005,16(8):1320-1325.

共引文献17

同被引文献33

引证文献7

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部